Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine Technology|February 26, 2005
False-positive "necklace sign" on whole-body thyroid cancer survey--a case reportSylvain Beaulieu, David Djang, Satoshi Minoshima
Clinical Nuclear Medicine|September 22, 2007
Chilaiditi sign on FDG-PETFélix-N Roy, Sylvain Beaulieu, Luc Boucher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 24, 2009
Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patientsFélix-Nicolas Roy, Sylvain Beaulieu, Luc Boucher, et al.
AJR. American Journal of Roentgenology|March 25, 2004
Positron emission tomography of schwannomas: emphasizing its potential in preoperative planningSylvain Beaulieu, Brian Rubin, David Djang, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2009
Impact of human serum albumin on oritavancin in vitro activity against enterococciGeoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, et al.
International Journal of Antimicrobial Agents|October 13, 2009
Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenesFrancis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, et al.
Diagnostic Microbiology and Infectious Disease|September 15, 2009
Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureusFrancis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Assessment of oritavancin serum protein binding across speciesFrancis F Arhin, Adam Belley, Geoffrey McKay, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2009
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faeciumGeoffrey A McKay, Sylvain Beaulieu, Francis F Arhin, et al.
Pageof 2